Brief: Tiziana Life Sciences Doses First Patient In Phase 2 Alzheimer’S Clinical Trial
17/12/2025 14:44
Dec 17 (Reuters) - Tiziana Life Sciences Ltd TLSA.O: TIZIANA LIFE SCIENCES DOSES FIRST PATIENT IN PHASE 2 ALZHEIMER’S CLINICAL TRIAL TIZIANA LIFE SCIENCES LTD - INTERIM DATA FOR ALZHEIMER'S TRIAL EXPECTED IN 2026 Source text: ID:nGNX6FtHZ Further company coverage: TLSA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study